{"Clinical Trial ID": "NCT00975676", "Intervention": ["INTERVENTION 1:", "- Triptorelin plus tamoxifen", "Determination of estrogen levels in blood samples of patients treated with triptorelin and tamoxifen for 5 years.", "INTERVENTION 2:", "Triptorelin Plus Exemestane", "Determination of estrogen levels in blood samples of patients treated with triptorelin plus exemestane for 5 years."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "A resected breast cancer confirmed histologically", "- Simultaneous registration in clinical trial IBCSG-2402 (SOFT trial) required", "- randomised to receive triptorelin in combination with tamoxifen citrate or exemestane", "- Hormonal receptor status:", "Positive oestrogen receptor and/or progesterone tumour", "CHARACTERISTICS OF PATIENTS:", "Premenopausal", "THERAPE PRIOR CONCURENT:", "See Disease Characteristics"], "Results": ["Performance measures:", "The levels of estrogen (Estradiol [E2], Estrone [E1] and estrone sulphate [E1S]) at different times during the first 4 years of treatment with triptorelin (Trip) in combination with tamoxifen (T) or exemestane (E), IBCSG 24-02 SOFT-EST Sub-study", "The estrogen concentrations (estradiol [E2], estrone [E1] and estrone sulphate [E1S]) were measured at the following times for TSE-SOFT: 0 (baseline), 3, 6, 12, 18, 24, 36 and 48 months after randomization.", "Duration: 0 (base), 3, 6, 12, 18, 24, 36 and 48 months after randomization", "Results 1:", "Title of the arm/group : Triptorelin Plus Tamoxifen", "Description arm/group: Determination of estrogen levels in blood samples of patients treated with triptorelin and tamoxifen for 5 years.", "Total number of participants analysed: 26", "Average (standard deviation)", "Unit of measurement: estradiol levels (E2) pg/mL at baseline (0 months): 26 participants", "- 109.81 (119.151)", "Level of estradiol (E2) at 3 months: 25 participants", "- 4,876 (7,123)", "\u2022 Estradiol level (E2) at 6 months: 24 participants", "- 3,761 (2.02)", "- Estradiol level (E2) at 12 months: 20 participants", "- 4.013 (2.765)", "- Estradiol level (E2) at 18 months: 20 participants", "\u00b7 7,306 (16,325)", "\u2022 Level of estradiol (E2) at 24 months: 15 participants", "4.453 (3.347)", "\u2022 Estradiol level (E2) at 36 months: 14 participants", "\u00b7 3,704 (2,138)", "- Estradiol level (E2) at 48 months: 14 participants", "5.914 (8,959)", "\u2022 Estrone rate (E1) at base (0 months): 26 participants", "- 60.27 (52.4)", "Estrone level (E1) at 3 months: 25 participants", "- 17,8 (6,73)", "Estrone level (E1) at 6 months: 24 participants", "- 18,66 (7.54)", "Estrone level (E1) at 12 months: 21 participants", "19.05 (8.4)", "Estrone level (E1) at 18 months: 20 participants", "- 18,64 (9,35)", "Estrone level (E1) at 24 months: 15 participants", "- 18.96 (7.63)", "Estrone level (E1) at 36 months: 14 participants", "19.49 (7.32)", "Estrone level (E1) at 48 months: 14 participants", "\u00b7 19.14 (7.24)", "Estrone sulphate (E1S) at base (0 months): 26 participants", "1437 (1825.06)", "\u00b7 Estrone sulphate levels (E1S) at 3 months: 25 participants", "281.4 (183.44)", "\u2022 Estrone sulphate level (E1S) at 6 months: 24 participants", "- 259 (167.23)", "Estrone sulphate level (E1S) at 12 months: 21 participants", "278.5 (236.38)", "Estrone sulphate level (E1S) at 18 months: 20 participants", "281.8 (160.6)", "\u2022 Estrone sulphate levels (E1S) at 24 months: 14 participants", "- 242.6 (96.75)", "Estrone sulphate levels (E1S) at 36 months: 14 participants", "\u00b7 244.4 (113.27)", "\u2022 Estrone sulphate level (E1S) at 48 months: 13 participants", "231.1 (93.46)", "Results 2:", "Title of the arm/group: Triptorelin Plus Exemestane", "Description arm/group: Determination of estrogen levels in blood samples of patients treated with triptorelin plus exemestane for 5 years.", "Total number of participants analysed: 83", "Average (standard deviation)", "Unit of measurement: estradiol levels (E2) pg/mL at baseline (0 months): 81 participants", "96.55 (151.235)", "Level of estradiol (E2) at 3 months: 67 participants", "3.973 (8.439)", "- Estradiol level (E2) at 6 months: 66 participants", "3 672 (8.06)", "- Estradiol level (E2) at 12 months: 68 participants", "2.486 (5)", "- Estradiol level (E2) at 18 months: 65 participants", "\u00b7 2.527 (6 204)", "Level of estradiol (E2) at 24 months: 62 participants", "- 2.52 (6.566)", "Level of estradiol (E2) at 36 months: 60 participants", "- 1.654 (2.764)", "Eastradiol level (E2) at 48 months: 50 participants", "- 9.073 (57,307)", "\u2022 Estrone levels (E1) at base (0 months): 81 participants", "- 65.42 (78.12)", "Estrone level (E1) at 3 months: 67 participants", "- 2.93 (3.33)", "Estrone level (E1) at 6 months: 66 participants", "2.73 (3.12)", "Estrone level (E1) at 12 months: 68 participants", "3.71 (6.35)", "Estrone level (E1) at 18 months: 65 participants", "- 8.47 (33.42)", "Estrone level (E1) at 24 months: 62 participants", "4.69 (9.16)", "Estrone level (E1) at 36 months: 60 participants", "4.93 (9.16)", "Estrone level (E1) at 48 months: 50 participants", "- 8.53 (35.07)", "Estrone sulphate (E1S) at base (0 months): 81 participants", "1371 (1763.84)", "\u2022 Estrone sulphate level (E1S) at 3 months: 67 participants", "- 56.02 (133.71)", "Estrone sulphate level (E1S) at 6 months: 66 participants", "58.7 (97.66)", "Estrone sulphate level (E1S) at 12 months: 68 participants", "- 47.31 (130.45)", "\u2022 Estrone sulphate level (E1S) at 18 months: 64 participants", "- 63.52 (175.19)", "\u2022 Estrone sulphate levels (E1S) at 24 months: 59 participants", "- 73.56 (258.29)", "Estrone sulphate levels (E1S) at 36 months: 60 participants", "- 53.27 (151.03)", "Estrone sulphate level (E1S) at 48 months: 46 participants", "- 112 (556.81)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/0", "Adverse Events 2:", "Total: 0/0"]}